July 2005 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

July 2005

Pharmaceutical Technology

The group also is exploring how various molecules affect the self-assembly chemistry and how to make the spheres monodispersive. "We're now trying to make the chemistry such that the spheres will all be the same size. And we're on the right track," says Wong.

Kaylynn Chiarello

1An in-depth discussion of the methodology is presented elsewhere (Adv. Mater. 17, 1145-1150 [2005]).


It Helps to be Flexible: Supple WIN Compounds Could Cure the Common Cold

A wiggling WIN antiviral compound (which received its name from the former Sterling-Winthrop company) could be the answer for fighting the common cold, says a team of Purdue University (West Lafayette, IN, http://www.purdue.edu/) researchers.

The rhinovirus—one cause for the common cold—has two main properties that make it difficult to stop. First, the virus can go incognito by subtly changing its surface structure and making it undetectable by the body's immune system. Second, after the virus enters the cell, it opens up a trap door to unleash RNA that instructs the cell to produce more rhinovirus particles.

A small, cigar-shaped cavity located in the folds of the VP-1 protein on the viral shell helps guide these changes. Filling this crevice prevents the virus from shape shifting and is the key to curing the cold, say the Purdue researchers. "What we'd like to do is find something that will stabilize these VP-1 proteins so the trap door can't open, and WIN compounds are potential compounds for the job," said Carol B. Post, professor at Purdue, in a press release.

By using computer simulations of the molecule's structure, the team has discovered that the WIN compound's flexible nature allows it to wiggle into this gap. Once inside the cavity, the molecule affects the VP-1 protein's rigidity, thereby deactivating the virus. Said Post, "In essence, the compounds can get tangled up in the protein so it can't move enough to let the RNA out. One reason WIN compounds are promising is that they are very good at getting to the spot where they can tangle up the protein effectively, which turns out to be a tricky business."

Researchers speculate the stiffness may also inhibit the virus from opening its trap door because, just as people don't like exercising after a big meal, "having a WIN compound in its cavity may be the VP-1 protein's equivalent of having an overly full stomach," noted Post.

Kaylynn Chiarello


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here